ClinicalTrials.gg
CompletedNCT02405260AGATAUpdated Feb 10, 2017

Add Glucokinase Activator to Target A1c

A Phase 2 interventional study of TTP399 400 mg and TTP399 800 mg in Diabetes Mellitus, Type 2, sponsored by vTv Therapeutics. Completed at 20 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-02-10.

Sponsored by vTv Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States — 343 open to participants now, 478 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
1,035th of 2,957
190 · median 90
Started
2015
with 114 others
Phase 2
391 of 3,304
24 open now
Registered
1,684th of 3,304
by date

Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 1,035th largest by enrollment of the 2,957 interventional ones that give a count, is one of 115 that started in 2015, is one of 391 in phase 2, and was the 1,684th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

343 of the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

338 more — sign in →

All 343 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

This trial is a multi-center, adaptive, randomized, double-blind, placebo- and active- controlled, parallel group, Phase 2 study in subjects with T2DM to evaluate the effect of TTP399 on HbA1c following administration for 6 months.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A historical diagnosis of Type 2 Diabetes in accordance with the American Diabetes Association (ADA) guidelines, with diagnosis at least 6 months prior to Screening.
  • On a stable (for the last 3 months prior to screening) regimen of metformin monotherapy equivalent of at least 1000 mg once daily.
  • Males, females of (must have a negative pregnancy test and be willing to comply with protocol ), and females of non-childbearing potential.
  • Age 18 to 75 years, inclusive, at the time of screening.
  • ≥7.0% and ≤9.5%.
  • Generally stable health without active infection or history of major surgery or significant injuries within the last year.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of Type 1 diabetes mellitus, maturity-onset diabetes of the young, insulin-requiring Type 2 Diabetes, other unusual or rare forms of diabetes mellitus, or history of diabetic ketoacidosis.
  • abnormal lab values including \<50ml/min/1.73m2, , or AST >1.5 X , hypokalemia or other clinically significant electrolyte abnormality.
  • History of myocardial infarction, unstable angina, coronary revascularization, stroke, or within 2 years of screening.
  • Presence of symptomatic congestive heart failure.
  • History of cardiac arrhythmias requiring treatment or prophylaxis with drugs or devices during the last 2 years or any history of atrial fibrillation or flutter beyond a single short-term episode (e.g., lasting 1-2 days).
  • History or presence of a 2nd degree or greater atrioventricular block in the absence of a pacemaker.
  • A 12-lead , from screening or baseline demonstrating interval >450 msec for males or >47 msec for females.
  • A family or personal history of long QT syndrome.
  • History of pancreatitis.
  • Persistent, uncontrolled hypertension.
  • Presence of chronic active hepatitis (, , nonalcoholic steatohepatitis [NASH]) and/or known liver cirrhosis.
  • Participation in any formal weight loss program, or fluctuation of > 5% in body weight, or having received medications approved for weight loss within 3 months prior to screening.
  • A positive pre-study drug screen.
  • Participation in a clinical trial and receipt of an product within 30 days.
  • Have a history of drug abuse within 2 years of screening or a positive pre-screen drug screen.
  • Have a history of hypoglycemic episode requiring glucose, glucagon, or orange juice administered by someone other than the patient within 6 months prior to screening.
  • A history of excessive alcohol consumption within the last 2 years prior to screening
  • Mental or legal incapacitation.
  • Blood donation of approximately 1 pint (500 mL) within 8 weeks.
  • History of MEN-2 or family history of medullary thyroid cancer.
  • History of cancer, other than non-melanoma skin cancer, that required therapy in the 5 years prior study start.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
190 participants (actual)

Study arms

  • Experimental
    TTP399 400 mg

    TTP399 once daily

    Drug: TTP399 400 mg

  • Experimental
    TTP399 800 mg

    TTP399 once daily

    Drug: TTP399 800 mg

  • Active comparator
    Sitagliptin 100 mg

    Sitagliptin once daily

    Drug: Sitagliptin 100 mg

  • Placebo comparator
    Placebo

    Placebo once daily

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in HbA1c (Glycosylated haemoglobin)

    Time frame: Day 1 to Day 168

Secondary outcomes

  1. HbA1c < 7% at 6 months

    Time frame: Day 1 to Day 168

  2. HbA1c < 6.5% at 6 months

    Time frame: Day 1 to Day 168

  3. Plasma Glucose Levels

    Time frame: Day 1 to Day 168

  4. Lipid Levels

    Time frame: Day 1 to Day 168

  5. Insulin Levels

    Time frame: Day 1 to Day 168

  6. Lactate Levels

    Time frame: Day 1 to Day 168

  7. C-peptide Levels

    Time frame: Day 1 to Day 168

  8. Glucagon Levels

    Time frame: Day 1 to Day 168

  9. Glucagon-like Peptide-1 Levels

    Time frame: Day 1 to Day 168

  10. Change in Body Weight

    Time frame: Day 1 to Day 168

  11. Adverse Events

    Time frame: Day 1 to Day 182

  12. Blood Pressure

    Time frame: Day 1 to Day 182

  13. Electrocardiogram Parameters

    Time frame: Day 1 to Day 182

  14. Hematology

    Time frame: Day 1 to Day 182

  15. Blood Chemistry

    Time frame: Day 1 to Day 182

  16. Urinalysis

    Time frame: Day 1 to Day 182

  17. Pulse

    Time frame: Day 1 to Day 182

07

Study locations

20 sites
  • Mesa, Arizona 85213, United States
  • Tuscon, Arizona 85741, United States
  • Canoga Park, California 91303, United States
  • Huntington Park, California 90255, United States
  • Los Angeles, California 90056, United States
  • West Hills, California 91307, United States
  • Centennial, Colorado 80112, United States
  • Littleton, Colorado 80127, United States
  • Waterbury, Connecticut 06708, United States
  • West Palm Beach, Florida 33409, United States
  • Gurnee, Illinois 60031, United States
  • Evansville, Indiana 47725, United States
  • Rochester, Minnesota 55905, United States
  • Greensboro, North Carolina 27408, United States
  • Moncks Corner, South Carolina 29461, United States
  • San Antonio, Texas 78209, United States
  • San Antonio, Texas 78229, United States
  • Schertz, Texas 78154, United States
  • Norfolk, Virginia 23507, United States
  • Richland, Washington 99352, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of Jul 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2015
First posted
Apr 1, 2015
Start
Mar 2015
Primary completionActual
Jul 2016
CompletionActual
Sep 2016
Results delay requested
Feb 9, 2017
Last update
Feb 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02405260
Lead sponsor
vTv Therapeutics
Responsible party
Sponsor
First posted
Apr 1, 2015
Start date
Mar 2015
Primary completion
Jul 2016
Completion
Sep 2016
Last update
Feb 10, 2017

Study contacts

Carmen Valcarce, Ph.D.
study chair · vTv Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TTP399

Start the discussion